A real-world study of limaprost tablets in the treatment of degenerative lumbar spinal stenosis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300076153

Enrollment

Unknown

Registered

2023-09-26

Start date

2023-12-12

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar spinal stenosis

Interventions

limaprost group:None

Usual treatment :None

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 40 years, gender is not limited; 2. Diagnosis of degenerative lumbar spinal stenosis; 3. Negative straight leg elevation test; 4. Presence of symptoms such as numbness, pain, and fatigue in the lower limbs; 5. Voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. The patient is pregnant or lactating; 2. Diagnosis of lumbar disc herniation; 3. Patients who believe that compliance is poor or may not be able to complete the task.

Design outcomes

Primary

Measure	Time frame
Percent change from baseline in JOA (Japanese Orthopaedic Association) subjective symptom score;Percent change from baseline in Oswestry Disability Index (ODI) ;Percent change from baseline in VAS score of pain and numbness ;EuroQol-5 Dimension (EQ-5D) questionnaire;maximum walking distance and time;pain-free walking distance;	—

Countries

China

Contacts

Public ContactWeishi Li

Peking University Third Hospital

wslee72@163.com+86 135 0135 8705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026